
|Articles|May 16, 2020
ASCRS 2020: Updates, improved injection technique from Eyepoint Pharmaceuticals
Author(s)Alex Delaney-Gesing
Advertisement
Ophthalmology Times' Sheryl Stevenson speaks with Eyepoint Pharmaceuticals' President/CEO Nancy Lurker and Chief Medical Officer Dario Paggiarino, MD, on the company's latest developments and research ahead of the ASCRS 2020 virtual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Precise Bio completes procedure using PB-001, a 3D-bioprinted corneal implant
2
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
3
EyePoint receives second consecutive positive recommendation from DSMC
4
Defining Retinal Vascular Diseases AMD, DME, RVO
5


















































.png)


